Pavlo Kot

Editas Medicine gains nod for clinical trial of EDIT-401 in cardiovascular disease

Editas Medicine gains nod for clinical trial of EDIT-401 in cardiovascular disease
Editas Medicine cleared for EDIT-401

Editas Medicine has received authorization to begin its first in human clinical trial of EDIT-401, targeting patients with hyperlipidemia.

This development marks a notable milestone for the company in the field of gene editing therapies, specifically addressing hereditary cardiovascular diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.